Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

• Päätekijät: Wei C. Yuet (Tekijä), Didi Ebert (Tekijä), Michael Jann (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: SAGE Publishing, 2021-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or "statins," which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United States Food and Drug Association di...